CC-5013 in Treating Patients With Red Blood Cell Transfusion-Dependent Myelodysplastic Syndromes and a Cytogenetic Abnormality

This study has been completed.

Study NCT00074126 Information provided by National Cancer Institute (NCI)

First Received: December 10, 2003 Last Updated: August 6, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	May 2009 (Final data collection date for primary outcome measure)

Publications:

List AF, Dewald G, Bennett J, et al.: Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. [Abstract] J Clin Oncol 23 (Suppl 16): A-5, 2s, 2005.